To determine the frequency of intracerebral haemorrhage (ICH) in patients taking antiplatelet therapy.

Abstract

Objectives: To determine the frequency of Intracerebral Haemorrhage (ICH) in patients taking antiplatelet therapy. Study Design: Cross-Sectional Study. Setting: Emergency Department at Ziauddin Hospital. Period: 2014-2016. Material & Methods: A total number of 75 patients with ICH, diagnosed by C.T Scan Brain Plain were included in this study. After the diagnosis of ICH on C.T scan Brain, patients were selected as with prior use of antiplatelets or secondary to other causes. Brief history was taken from the patients and attendants regarding the history of antiplatelets use. Results: The average ages of the patients were 59.97±12.46 years. There were 57.33% male and 42.67% female.  Out of 75 ICH patients 44% (33/75) were taking antiplatelet therapy. Median duration of APT was 12[IQR=24] months. Out of these 33 patients 78.8% (26/33) were taking single APT and 21.2% (7/33) were taking dual APT.  Mean age was significantly high in patients those who are on antiplatelet therapy as compare to those who was not on APT (p=0.033). Gender and systematic finding of patients were not significant those who are not on APT and on APT.  Comorbid like DM, HTN and IHD were significant high in patients on APT and in hospital mortality was also not significant in patients on APT and not on APT. Conclusion: In this study overall in hospital mortality was observed in 13.33%. These study suggests there is only modestly increased mortality in patients taking pre-ICH APT, and little or no increase in poor functional outcomes there are a substantial number of ICH patients taking pre-ICH APT who could be at risk. The pre-ICH APT mortality is correlated, which can be improved by therapies to restore normal platelet function which is uncertain and to demonstrate needs comparatively large trials, given the modest increase in risk. For the reduction in morbidity related to APT-ICH Prevention of risk factor like HTN is most antonyms strategy.